RecruitingPhase 1NCT07291232

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Subcutaneous Doses of ABBV-295 in Adult Subjects With Obesity

Sponsor

AbbVie

Enrollment

48 participants

Start Date

Nov 19, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity

Summary

This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ABBV-295 and a drug called Placebo for people with obesity. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGABBV-295

Subcutaneous Injections

DRUGPlacebo

Subcutaneous Injections

Locations(2)

CenExel ACT- Anaheim Clinical Trials /ID# 283200

Anaheim, California, United States

Acpru /Id# 278624

Grayslake, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07291232

Related Trials

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

NCT074073481 location

Effectiveness of Two Different Body Positions During Facemask Ventilation in Obese Patients

NCT063052731 location